ARTL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.5M
-6.8%
2.7M
-3.5%
2.8M
-9.8%
3.1M
-1.9%
3.1M
R&D
876.0K
+13.3%
773.0K
-13.4%
893.0K
-30.0%
1.3M
-31.9%
1.9M
SG&A
1.6M
-15.0%
1.9M
+1.2%
1.9M
+4.4%
1.8M
+41.8%
1.3M
Operating Income
-2505000
+6.8%
-2689000
+3.5%
-2786000
+9.8%
-3089000
+1.9%
-3150000
EBITDA
-2505000
+6.8%
-2689000
+3.5%
-2786000
+9.8%
-3089000
+1.9%
-3150000
Net Income
-2427000
+18.0%
-2958000
+29.0%
-4166000
-33.5%
-3120000
+3.1%
-3221000
EPS (Basic)
$-0.89
+77.8%
$-4.00
+5.7%
$-4.24
+64.4%
$-11.91
+29.4%
$-16.86
EPS (Diluted)
$-0.89
+77.8%
$-4.00
+5.7%
$-4.24
+64.4%
$-11.91
+29.4%
$-16.86
Shares (Diluted)
2.7M
+267.0%
739.0K
-24.8%
983.0K
+274.7%
262.3K
+37.3%
191.0K
Artelo Biosciences (ARTL) โ€” Financials